B.C. won’t cover hepatitis C drug that’s possible cure for woman infected with tainted blood

Lack of national pharmacare program makes it hard to negotiate better drug prices. The B.C. government says it won't cover the cost of a breakthrough treatment for hepatitis C for Nikky Davies, who contracted the virus through tainted blood she was administered in hospital. A Nanaimo, B.C., woman who contracted the hepatitis C virus through tainted blood has been denied a blockbuster new medication the province says is extremely expensive and would bankru

U.S.: Settlement Reached on Washington State Medicaid Denial of Pricey Hep C Drugs

The Health Care Authority on Monday reached a settlement agreement in a class action lawsuit that sought broader coverage of costly hepatitis C drugs for Medicaid patients in Washington state. The settlement has yet to be approved by a judge but lawyers are hopeful it will be soon. In the past several years, multiple pharmaceutical companies nationwide have developed direct-acting antiviral drugs that cure hepatitis C in more than 90 percent of patient

The Week in Review: Oct 23 – Oct 28, 2016

Friday, October-28-16 News in Brief Restricted Reimbursement for DAAs Hinders Progress Towards Global Hepatitis C Eradication Goal October 27, 2016 There are significant differences in the criteria for reimbursing for direct-acting antivirals (DAAs) for patients with hepatitis C virus (HCV) among the provinces in Canada, according to the results of a recent study. Conducted by Alison Marshall, MA, of The Kirby Institute, and colleagues, the study...